Published in Mol Carcinog on November 01, 2005
Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem (2008) 1.22
WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol (2010) 1.16
WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A (2014) 1.03
The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol (2008) 0.87
Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. Int J Mol Sci (2012) 0.87
Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: chemoprevention by budesonide and N-acetylcysteine. Proc Natl Acad Sci U S A (2006) 0.86
Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol (2007) 0.84
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. Cancer Lett (2009) 0.81
Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cancer Lett (2010) 0.79
WWOX modulates the ATR-mediated DNA damage checkpoint response. Oncotarget (2016) 0.79
WWOX, large common fragile site genes, and cancer. Exp Biol Med (Maywood) (2015) 0.78
Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma. Exp Biol Med (Maywood) (2014) 0.75
The role of WWOX polymorphisms on COPD susceptibility and pulmonary function traits in Chinese: a case-control study and family-based analysis. Sci Rep (2016) 0.75
Loss of Lung WWOX Expression Causes Neutrophilic Inflammation. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell (1996) 15.19
p53: puzzle and paradigm. Genes Dev (1996) 13.16
Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A (1992) 8.87
DNA excision repair. Annu Rev Biochem (1996) 6.71
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell (2000) 5.64
Molecular mechanism of nucleotide excision repair. Genes Dev (1999) 5.27
p53: death star. Cell (2000) 4.77
ATR regulates fragile site stability. Cell (2002) 4.74
DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol (1994) 4.14
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature (1974) 3.47
Constitutive fragile sites and cancer. Science (1984) 3.30
DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet (1984) 2.92
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer (2001) 2.61
Polycyclic aromatic hydrocarbons in the diet. Mutat Res (1999) 2.44
Fifty years of benzo(a)pyrene. Nature (1983) 2.42
The cellular response to p53: the decision between life and death. Oncogene (1999) 2.31
Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogene (1999) 2.29
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene (2003) 1.79
Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet (1998) 1.65
Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res (2002) 1.62
Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene (2002) 1.55
Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem (2003) 1.54
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res (2001) 1.46
WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res (2003) 1.42
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res (2003) 1.32
Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett (2003) 1.30
WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res (2003) 1.28
Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res (1998) 1.28
Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol (2000) 1.27
Caffeine and human DNA metabolism: the magic and the mystery. Mutat Res (2003) 1.25
Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer (2004) 1.22
Distribution and repair of photolesions in DNA: genetic consequences and the role of sequence context. Photochem Photobiol (1993) 1.20
FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol (2002) 1.19
Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem (2004) 1.11
Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells. Oncogene (2001) 1.07
The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer (2004) 1.05
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ (2002) 1.03
Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer (2002) 1.03
Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA (2001) 1.02
Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J Biol Chem (1999) 1.02
Common fragile sites and cancer (review). Int J Oncol (1998) 1.01
Relationship between excision repair and the cytotoxic and mutagenic effect of the 'anti' 7,8-diol-9,10-epoxide of benzo[a]pyrene in human cells. Mutat Res (1982) 1.01
Functional genomics of UV radiation responses in human cells. Mutat Res (2004) 0.99
Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer (2002) 0.99
Unique patterns of gene expression changes in liver after treatment of mice for 2 weeks with different known carcinogens and non-carcinogens. Carcinogenesis (2004) 0.94
Covalent bonding of bay-region diol epoxides to nucleic acids. Adv Exp Med Biol (1991) 0.94
Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites. Mol Cancer Res (2005) 0.89
Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res (1999) 0.88
Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. Int J Cancer (1998) 0.86
FHIT in human cancer. Adv Cancer Res (1998) 0.86
Diverse chemical carcinogens fail to induce G(1) arrest in MCF-7 cells. Carcinogenesis (2000) 0.85
Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis (1995) 0.85
A novel approach for analyzing the structure of DNA modified by Benzo[a]pyrene diol epoxide at single-molecule resolution. Chem Res Toxicol (2000) 0.83
Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. Mol Cell Biochem (2000) 0.83
UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp Cell Res (1999) 0.83
Induction of the common fragile site FRA3B does not affect FHIT expression. Oncogene (2001) 0.79
Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation. Biochem Biophys Res Commun (2004) 0.79
Effect of radiation and cigarette smoking on expression of FUdR-inducible common fragile sites in human peripheral lymphocytes. Mutat Res (1995) 0.78
Differential efficiency of mutagenesis at three genetic loci in CHO cells by a benzo[a]pyrene diol epoxide. Mutat Res (1988) 0.76
Disruption of transcription in vitro and gene expression in vivo by DNA adducts derived from a benzo[a]pyrene diol epoxide located in heterologous sequences. Carcinogenesis (1997) 0.76
Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics (2003) 3.06
Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A (2003) 2.50
Overdispersed logistic regression for SAGE: modelling multiple groups and covariates. BMC Bioinformatics (2004) 2.01
Late cornified envelope family in differentiating epithelia--response to calcium and ultraviolet irradiation. J Invest Dermatol (2005) 1.78
Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics (2005) 1.75
Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res (2004) 1.71
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res (2003) 1.48
WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene (2004) 1.47
Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res (2007) 1.45
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35
Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat (2005) 1.33
Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res (2007) 1.27
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
WWOX protein expression in normal human tissues. J Mol Histol (2006) 1.22
CARM1 promotes adipocyte differentiation by coactivating PPARgamma. EMBO Rep (2008) 1.21
Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One (2009) 1.18
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res (2002) 1.17
The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain (2013) 1.14
WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer (2007) 1.13
Activation of the canonical Wnt/β-catenin pathway in ATF3-induced mammary tumors. PLoS One (2011) 1.08
From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res (2004) 1.06
Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer (2006) 1.05
High-affinity triplex-forming oligonucleotide target sequences in mammalian genomes. Mol Carcinog (2007) 1.04
The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. BMC Cancer (2008) 1.02
Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog (2002) 1.02
Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells. Mol Carcinog (2007) 0.99
Response of human mammary epithelial cells to DNA damage induced by BPDE: involvement of novel regulatory pathways. Carcinogenesis (2003) 0.96
GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. Breast Cancer Res (2006) 0.96
A web-based search engine for triplex-forming oligonucleotide target sequences. Oligonucleotides (2006) 0.96
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis (2003) 0.95
SAGE profiling of UV-induced mouse skin squamous cell carcinomas, comparison with acute UV irradiation effects. Mol Carcinog (2005) 0.94
Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer. J Biol Chem (2012) 0.91
Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. PLoS One (2012) 0.89
Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. BMC Cancer (2009) 0.88
CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer. Mol Cancer Res (2007) 0.87
Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol (2007) 0.84
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer Prev Res (Phila) (2009) 0.83
Detoxication of sulfur half-mustards by nucleophilic scavengers: robust activity of thiopurines. Chem Res Toxicol (2010) 0.83
Protection against 2-chloroethyl ethyl sulfide (CEES)-induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway. Toxicol Appl Pharmacol (2011) 0.83
2,6-Dithiopurine blocks toxicity and mutagenesis in human skin cells exposed to sulfur mustard analogues, 2-chloroethyl ethyl sulfide and 2-chloroethyl methyl sulfide. Chem Res Toxicol (2010) 0.80
2,6-Dithiopurine, a nucleophilic scavenger, protects against mutagenesis in mouse skin treated in vivo with 2-(chloroethyl) ethyl sulfide, a mustard gas analog. Toxicol Appl Pharmacol (2012) 0.78
Karyotypic evolution of four novel mouse mammary carcinoma cell lines. Identification of marker chromosomes by fluorescence in situ hybridization. Cancer Genet Cytogenet (2003) 0.77
Quantitative high-throughput measurement of gene expression with sub-zeptomole sensitivity by capillary electrophoresis. Anal Biochem (2005) 0.75